U.S. Markets closed

Sunesis provides update for VALOR Phase 3 Trialof vosaroxin plus cytarabine

VALOR enrollment reaches 500 patients. Enrollment in the VALOR Trial, a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin plus cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML), has reached 500 patients. Target enrollment of 675 patients is expected to be complete in 2013, with unblinding of the study data expected in the first half of 2014. VALOR is the largest company-sponsored trial ever conducted in first relapsed or refractory AML. Enrollment doubles in LI-1 trial. Enrollment in the Less Intensive 1, or LI-1, study, a Phase 3 randomized, controlled trial evaluating novel treatment regimens, including two vosaroxin-containing regimens, in newly diagnosed elderly AML and high-risk myelodysplastic syndrome patients, has reached 49 vosaroxin-treated patients. LI-1 is being conducted by the United Kingdom's National Cancer Research Institute under the direction of Professor Alan K. Burnett, Head of Haematology at Cardiff University.